AVITA Medical, Inc.

AVITA Medical, Inc. is a commercial-stage regenerative medicine company dedicated to acute wound care and skin restoration. The company's mission centers on transforming lives through innovative skin healing technologies, aiming to optimize wound healing and accelerate patient recovery. Its principal executive offices are located in Valencia, California, United States.

At the forefront of AVITA Medical's product portfolio is the RECELL System, an FDA-approved device that utilizes a small sample of a patient's own skin to generate "Spray-On Skin" cells. This technology is used for the treatment of thermal burn wounds, full-thickness skin defects, and for the repigmentation of stable depigmented vitiligo lesions. In the United States, AVITA Medical also holds exclusive rights to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and Cohealyx, an AVITA Medical-branded collagen-based dermal matrix. Globally, the RECELL System is approved for various applications, including thermal burn and trauma wounds, and holds CE-mark approval in Europe, TGA certification in Australia, and PMDA approval in Japan.

Recent leadership changes saw Cary Vance appointed as President and Chief Executive Officer in April 2026, with Jan Stern Reed named Chair of the Board. The company also secured a 10-year agreement, valued at up to $25.5 million, with the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield. This agreement aims to bolster national preparedness for burn mass casualty incidents. AVITA Medical maintains its position as a leading therapeutic acute wound care company, focused on expanding its market presence and product offerings.